🫂 #ASCOAI: Supportive cancer care is about more than treatment. Early findings suggest the AI-based HelpCan91 platform may enable earlier toxicity detection, faster clinician response, & better symptom monitoring for patients with cancer. Learn more ➡️ https://ow.ly/t42j50ZkQFC

🧠 Phase II UNITED trial: MRI-guided adaptive #radiotherapy may improve precision in high-grade glioma. ☑️ 4% marginal failure rate ☑️ Successful margin de-escalation ☑️ Favorable safety profile 👨‍⚕️ Jay Detsky, MD, PhD 🔗 https://ascopost.com/news/june-2026/mri-guided-radiotherapy-in-high-grade-glioma/

🩸 A new risk score may help personalize anticoagulation for cancer-associated venous thromboembolism. The ONCO-DOAC BLEED score stratified major bleeding risk in patients on direct oral anticoagulants. 🔹 Naohiko Nakanishi, MD, PhD | #CardioOncology https://ow.ly/YN3p50ZkQB1

🫀Cardioprotective therapies may help preserve heart function during cancer treatment. A new meta-analysis supports RAAS inhibitors and beta-blockers while highlighting the need for more cardio-oncology research. 🔹 Wouter Meijers, MD, PhD 🔗 https://ow.ly/6rHg50ZiEQp

🫂 Early palliative care can make a meaningful difference for patients with breast cancer Data shows integrating supportive care at diagnosis improved quality of life, reduced symptom burden more than on-demand care. 🔹 Himanshu Varshney, MD https://ow.ly/MaoL50ZglB0

🫁 ASCO has updated its living guideline for stage IV NSCLC without driver alterations. Based on the phase III POD1UM-304 trial, retifanlimab + platinum-based chemotherapy is now a recommended first-line option for eligible patients. Learn more 👉 https://ow.ly/ibxw50ZiEPt

💻 AI may redefine how response is measured in pleural mesothelioma. ARTIMES: ☑️ Outperformed RECIST criteria, human assessments ☑️ Detected progression 38 days earlier ☑️ Improved prediction of patient outcomes Explore the findings ➡️ https://ow.ly/EL2K50ZglEC

🖥️ AI-derived mammogram risk scores may function as dynamic biomarkers for breast cancer. Risk trajectories diverged up to 6 years before diagnosis, supporting more personalized screening & prevention. 👩‍⚕️ Constance D. Lehman, MD, PhD 🔗 https://ow.ly/3NR850ZiEOR

ASCO AI: ASCO Guidelines are now integrated into OpenEvidence The collaboration enables clinicians to access ASCO guideline-based recommendations, flowcharts, and supporting evidence directly through the AI platform. Learn more 👉 https://ow.ly/7AI750Zg1I7

🎗️ Global collaboration is critical to improving pediatric cancer outcomes St. Jude has been redesignated as a WHO Collaborating Centre for Childhood Cancer, reinforcing efforts to strengthen health systems, expand access to care, and improve outcomes. 🔗 https://ow.ly/jJcl50ZfmEs

🩸 #ASCOAI: Could a blood test predict #lungcancer ahead of diagnosis? 🫁 A machine learning–derived plasma protein signature can identify future lung cancer risk >5 years before diagnosis and was used in assessment of possible preventive treatment. 🔗 https://ow.ly/n4FQ50ZfmCj

✅ Expanding options in #BladderCancer: Phase II SURE-01 data suggest reduced-dose neoadjuvant sacituzumab govitecan has promising activity in muscle-invasive disease for patients unable or unwilling to receive chemotherapy. 🔹 Andrea Necchi, MD 🔗 https://ow.ly/9nTC50ZeKWY

⚠️ The FDA is warning of an ongoing shortage of stereotactic breast biopsy needles that could affect #breastcancer diagnostic care through early 2027. Providers are being encouraged to conserve supplies, diversify vendors, and communicate possible delays. https://ow.ly/Apyi50ZeKVP

☢️ New phase II data support the potential of Lu-177 dotatate in metastatic pancreatic neuroendocrine tumors. ➡️ longer PFS & better QoL vs sunitinib ➡️ late grade 2+ AEs could impact subsequent therapy 🔹 Eric Baudin, MD https://ow.ly/ixEG50Zep0G

🔟 -year FAST-Forward data support 1-week adjuvant radiotherapy as a standard option in breast cancer. The 26 Gy/5-fraction schedule showed disease control and safety for treatment to the breast or chest wall. 🔸 Adrian Murray Brunt, FRCR https://ow.ly/VTob50ZeoZA

🩸 AI may reduce biological noise in liquid biopsies The plasmaCHORD model uses cfDNA fragmentation patterns to identify if mutations originate from tumors or white blood cells ➡️ More accurate treatment decisions 🔸 Jenna Canzoniero, MD, MS https://ow.ly/n1rM50ZcSIE

💻 ASCO AI: AI in oncology operations Mia, Moffitt Cancer Center’s AI-powered information assistant, is helping reduce imaging delays, improve patient satisfaction, and free clinical teams to focus on higher-touch patient care. Learn more 👉 https://ow.ly/G9lJ50ZcSHx

🩸HPV-DeepSeek, a WGS assay, detected molecular recurrence in patients with HPV-associated #HeadAndNeckCancer up to 17.5 months before clinical recurrence and nearly twice as early as ddPCR. 🔹 Daniel Faden, MD Explore the findings ➡️ https://ow.ly/IIit50Zcn49

🩺 Geriatric assessments are an important tool for modern #cancercare. Stuart Lichtman, MD, FACP, FASCO, urges moving beyond ECOG, Karnofsky performance status to better identify vulnerabilities, predict toxicity, & personalize treatment for older adults with #cancer. 🔗 https://ow.ly/y90i50ZbWfY

🌎 Every patient. Every cancer. Everywhere. Eric J. Small, MD, FASCO, 2025-2026 ASCO President, shares his vision for translating scientific breakthroughs into meaningful outcomes across cultures, health systems, and resource settings worldwide. 🔗 https://ow.ly/YUPJ50ZbWcH

🧠 ASCO AI: CNSPredict, a machine learning clinicogenomic model, identified patients with metastatic breast cancer at high risk for brain metastases, including a subgroup with a 26% 2-year incidence rate. 🗣️ Presented by Luke R.G. Pike, MD, at ASCO 2026 🔗 https://ow.ly/bFfw50ZbNBh

🇭🇹 What does it take for a cancer prevention program to survive after its founder is gone? In this powerful reflection, Danta Bien-Aimé, BSN, RN, MMSc-GHD, explores the challenges of sustaining cervical cancer screening and treatment access in Haiti. 🔗 https://ow.ly/Ri0z50ZbNzR

🩺 The Society of Gynecologic Oncology has named Matthew A. Powell, MD, as its 2026 President. Dr. Powell's priorities include advancing education, member engagement, advocacy, and wellness across the gynecologic oncology community. https://ow.ly/zgPI50ZbNyt

🖥️ ASCOAI: Can AI support complex clinical reasoning? A study in Science found OpenAI {bot} o1 model outperformed physicians across several diagnostic and management reasoning tasks ➡️ Potential for AI as a clinical decision support tool. 🔗 https://ow.ly/tYC850ZabBi

🎶 New #survivorship data suggest music therapy may be a powerful tool for anxiety management. In the MELODY trial, music therapy matched CBT for reducing anxiety among cancer survivors, and improved fatigue, insomnia, mood, and quality of life. 🔗 https://ow.ly/XQXM50ZabzB

🔬The phase III NRG/RTOG 1005 trial found concurrent radiation boost during whole-breast irradiation was noninferior to sequential boost for ipsilateral breast recurrence in high-risk early #breastcancer. 🔸 Frank Vicini, MD, FACR, FASTRO, FABS https://ow.ly/kZTl50Z2Pb5

🆕 In the largest, multinational analysis of external beam RT in early-stage #HCC, survival outcomes were comparable to surgery, ablative therapies. ➡️ Supports broader role for RT in treatment planning 🔺 Maria Reig, MD, PhD Explore findings: https://ow.ly/gKa750Z9Rzc

🦠 Real-world evidence may help improve ADC safety Researchers found infection and hematologic AE risks varied substantially across antibody-drug conjugates, underscoring the importance of proactive monitoring. 🔸Jan et al | Cancers Learn more: https://ow.ly/oMJ450Z9Ryb

💊 A new all-oral regimen may ease treatment burden for older/frail patients with AML. In ASCERTAIN V, decitabine/cedazuridine + venetoclax induced CRs in 47%. ➡️ Study led to recent #FDA approval 🔹 Gail J. Roboz, MD | New England Journal of Medicine 🔗 https://ow.ly/YXoF50Z9RwT

🧬 In HPV-negative, PD-L1–positive, recurrent/metastatic HNSCC, ficerafusp alfa + pembrolizumab demonstrates: • 21% CR rate • Median OS: 21.3 months • Median response duration: 21.7 months 🔸 Glenn J. Hanna, MD of Dana-Farber 🔗 https://ow.ly/V2VI50Z2P9P